Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Multicentric Randomized Phase III Trial Comparing Methotrexate and Cetuximab in First-line Treatment of Recurrent and/or Metastatic Squamous Cell Head and Neck Cancer in Elderly Unfit Patients According to Geriatric Evaluation

Trial Profile

Multicentric Randomized Phase III Trial Comparing Methotrexate and Cetuximab in First-line Treatment of Recurrent and/or Metastatic Squamous Cell Head and Neck Cancer in Elderly Unfit Patients According to Geriatric Evaluation

Active, no longer recruiting
Phase of Trial: Phase III

Latest Information Update: 21 Aug 2018

At a glance

  • Drugs Cetuximab (Primary) ; Methotrexate
  • Indications Head and neck cancer
  • Focus Therapeutic Use
  • Acronyms ELAN-UNFIT
  • Most Recent Events

    • 09 Aug 2018 Status changed from recruiting to active, no longer recruiting.
    • 09 Aug 2018 Planned End Date changed from 1 Jun 2019 to 1 Aug 2023.
    • 09 Aug 2018 Planned primary completion date changed from 1 Jun 2017 to 1 Nov 2018.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top